Register | Login
Intellectual Property Today
RFC Express - Document Management System
2013 Top Patent Firms
2013 Top Trademark Firms
Current Issue

Advertising Opportunities

Click Here

Email A Friend Back to Archived News

AbSorber Receives European Patent Protection for Its Transplantation Cross Match-Test XM-ONE

Tuesday, December 08, 2009

Stockholm, Sweden -- AbSorber has received patent protection for its transplantation cross match-test XM-ONE® in the European countries. The patent was previously approved in New Zealand which was the first country to approve a patent for AbSorbers product. The European countries are highly prioritized markets for AbSorber and the patent approval is an important milestone in Absorbers intellectual property strategy.

The patent was granted by the European Patent Office (EPO) and AbSorber has also patent applications pending for XM-ONE® in the US, Japan and other key transplantation markets. The company expects more countries to follow the European approval of the XM-ONE® patent.

XM-ONE® is unique in that it is the first standardized test that can detect antibodies against the cells that line the inside of blood vessels. These endothelial cells are the first point of contact between the transplanted organ and the recipient’s immune system. Anti-endothelial cell antibodies have been shown to play a key role in causing post-transplantation rejections.

AbSorber is subsidiary to LinkMed, a listed private equity company investing in life science companies.

For more information visit

AbSorber develops products that facilitate more successful transplantations. AbSorber’s first product, the transplantation test XM-ONE® detects key antibodies responsible for post-transplantation rejections. XM-ONE® is already CE marked and FDA approved for sales in the EU and U.S. AbSorber has a distribution and sales agreement with Olerup International AB.

Back to Archived News
Looking for...

  © Copyright 2013 Intellectual Property Today
Download Adobe Reader for free